
Opinion|Videos|February 8, 2024
Overall Survival Update for KEYNOTE-564 in Renal Cell Carcinoma
Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































